Recombinant Human Glutamic Acid Decarboxylase

Recombinant Human Glutamic Acid Decarboxylase Uses, Dosage, Side Effects, Food Interaction and all others data.

Recombinant Human Glutamic Acid Decarboxylase (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.

The immune system of patients treated with Recombinant Human Glutamic Acid Decarboxylase demonstrate an increase in the secretion of several immunomodulatory substances, dominated by regulatory cytokines, including IL5, IL13, IL10, IL17, IFN-a and TNF-a. Additionally, the activity of T-cells in response to GAD65 is increased with Recombinant Human Glutamic Acid Decarboxylase therapy and subjects receiving Recombinant Human Glutamic Acid Decarboxylase show an up regulation of cytokines in response to GAD65.

Table Of contents

• Recombinant Human Glutamic Acid Decarboxylase
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Recombinant Human Glutamic Acid Decarboxylase
Generic	rhGAD65
rhGAD65 Other Names	Recombinant human GAD65, Recombinant human glutamic acid decarboxylase
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Investigated for use/treatment in diabetes mellitus type 1.

Innovators Monograph

You find simplified version here Recombinant Human Glutamic Acid Decarboxylase